Metagenomi officer granted options and RSUs

Wein Matthew reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Wein Matthew reported acquisition or exercise transactions in this Form 4 filing.

Metagenomi Therapeutics officer Matthew Wein received new equity awards. On April 1, 2026, he was granted options to buy 68,000 shares of common stock at $1.34 per share, expiring on March 31, 2036. The option vests 25% on April 1, 2027, with the rest in 36 equal monthly installments, contingent on continued service. He was also granted 11,000 restricted stock units that begin vesting 25% on June 5, 2027, then in 12 equal quarterly installments. Following these compensation-related grants, his direct common stock holdings total 125,549 shares.

Insider Trade Summary

Grant/Award: 79,000 shares

Grant/Award 2 txns

Insider Wein Matthew

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	68,000	$0.00	$0.00
Grant/Award	Common Stock	11,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 68,000 contracts (Direct); Common Stock — 125,549 shares (Direct)

Footnotes (2)

1. F1. These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2027, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
2. F2. 25% of the shares subject to this option shall vest and become exercisable on April 1, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

Key Figures

Stock options granted: 68,000 shares Option exercise price: $1.34 per share Option expiration date: March 31, 2036 +5 more

8 metrics

Stock options granted 68,000 shares Option grant on April 1, 2026

Option exercise price $1.34 per share Stock Option (Right to Buy) on common stock

Option expiration date March 31, 2036 End of option term for 68,000-share grant

RSUs granted 11,000 units Common stock RSU award on April 1, 2026

RSU initial vesting 25% on June 5, 2027 First vesting tranche for 11,000 RSUs

RSU remaining vesting 12 equal quarterly installments Remaining RSU vesting after June 5, 2027

Post-grant common shares held 125,549 shares Direct common stock holdings after April 1, 2026 grant

Option vesting schedule 25% on April 1, 2027; rest over 36 months Vesting pattern for 68,000-share option grant

Key Terms

restricted stock units ("RSUs"), vest, stock option, quarterly installments, +1 more

5 terms

restricted stock units ("RSUs") financial

"These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2027,"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

vest financial

"25% of the RSUs shall vest on June 5, 2027, with the remainder vesting in 12 equal quarterly installments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

stock option financial

"25% of the shares subject to this option shall vest and become exercisable on April 1, 2027,"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

quarterly installments financial

"with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service"

monthly installments financial

"with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service"

Monthly installments are regular, fixed payments made each month to gradually pay off a larger amount, such as a loan or purchase. Think of it like paying for a big item in small, manageable parts instead of all at once. For investors, understanding installment payments helps gauge how debts are structured and how they might affect financial stability or cash flow over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity awards did Metagenomi Therapeutics (MGX) grant to Matthew Wein?

Metagenomi Therapeutics granted Matthew Wein new stock options and restricted stock units as compensation. He received options for 68,000 common shares at $1.34 per share and 11,000 RSUs, both subject to multi-year vesting schedules tied to his continued service with the company.

How many Metagenomi Therapeutics (MGX) stock options did Matthew Wein receive and at what price?

Matthew Wein received stock options for 68,000 shares of Metagenomi Therapeutics common stock at an exercise price of $1.34 per share. These options vest over four years and expire on March 31, 2036, aligning his potential upside with the company’s long-term performance and retention.

What are the vesting terms for Matthew Wein’s Metagenomi (MGX) restricted stock units?

Wein’s 11,000 restricted stock units vest over several years based on continued service. 25% of the RSUs vest on June 5, 2027, with the remaining units vesting in 12 equal quarterly installments thereafter, gradually converting into common shares as conditions are met.

How do the new equity grants affect Matthew Wein’s Metagenomi (MGX) share ownership?

After the April 1, 2026 grants, Wein directly holds 125,549 Metagenomi common shares. The new 11,000 RSUs and 68,000 options add potential future equity exposure, but they vest over time and the options must be exercised at $1.34 per share when vested.

Are Matthew Wein’s Metagenomi (MGX) Form 4 transactions open-market purchases or compensation grants?

The reported transactions are compensation-related grants, not open-market purchases or sales. Both the 68,000 stock options and 11,000 RSUs were awarded at a per-share price of $0.00, with vesting schedules that depend on Wein’s continued service with Metagenomi Therapeutics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/03/2026 - 02:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wein Matthew

(Last) (First) (Middle)

C/O METAGENOMI THERAPEUTICS, INC.

5959 HORTON STREET, 7TH FLOOR

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Metagenomi Therapeutics, Inc. [ MGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		A		11,000(1)	A	$0	125,549	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.34	04/01/2026		A		68,000		(2)	03/31/2036	Common Stock	68,000	$0	68,000	D

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2027, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

2. 25% of the shares subject to this option shall vest and become exercisable on April 1, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

Remarks:

Title: General Counsel, Compliance Officer and Corporate Secretary

	/s/ Matthew L. Wein	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)